Lipid-based drug delivery systems (LBDDS) are one of the most studied bioavailability
enhancement technologies and are utilized in a number of US Food and Drug …

The improved safety profile and antifungal efficacy of liposomal amphotericin B (LAmB)
compared to conventional amphotericin B deoxycholate (DAmB) is due to several factors …

This review describes the pharmacokinetic properties of the systemically administered
antileishmanial drugs pentavalent antimony, paromomycin, pentamidine, miltefosine and …

Amphotericin B (AmB) is a very effective antifungal and antiparasitic drug with a narrow
therapeutic window. To improve its efficacy/toxicity balance, new controlled release …

In the present study, a Poloxamer 407-based amphotericin B (AmpB)-containing polymeric
micelles system (AmpB/M) was employed in the treatment of Leishmania amazonensis …

Purpose To investigate the biodistribution of amphotericin B (AmB) in mice and rats
following administration of liposomal AmB (AmBisome®) using a physiologically-based …

Since the 1950s, amphotericin B (AmB) has been used in the clinical practice to treat
systemic fungal infections and leishmaniasis, a neglected parasitic disease that can be fatal …

From the 1950s, Amphotericin B (AmB) in the form of Fungizone® was considered the “gold
standard” in antifungal therapy. This was due to its broad-spectrum of activity. In the 1990s …

Miltefosine (MTS) is the only approved oral drug for treating leishmaniasis caused by
intracellular Leishmania parasites that localize in macrophages of the liver, spleen, skin …

Today, more than a billion people—one-sixth of the world's population—are suffering from
neglected tropical diseases. Human African trypanosomiasis, Chagas disease, and …